• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Expanding nanoparticle multifunctionality: size-selected cargo release and multiple logic operations?
  Danlei Xiang Nanoscale, 2021,13, 5497-5506
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Excited state character of Cibalackrot-type compounds interpreted in terms of Hückel-aromaticity: a rationale for singlet fission chromophore design?
  Weixuan Zeng,Ouissam El Bakouri,Henrik Ottosson Chem. Sci., 2021,12, 6159-6171
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Professional Introduction to 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol (CAS No. 345642-90-2)

2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol, identified by its Chemical Abstracts Service (CAS) number 345642-90-2, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This heterocyclic organic molecule, featuring a pyrimidine core with dimethylamino and dimethyl substituents, has garnered attention due to its versatile structural framework and potential applications in medicinal chemistry. The compound’s unique electronic and steric properties make it a valuable scaffold for designing novel bioactive molecules.

The pyrimidine ring is a fundamental motif in many biologically relevant molecules, including nucleic acid bases and various pharmacologically active agents. The introduction of electron-donating dimethylamino groups at the 2-position and methyl groups at the 4- and 6-positions enhances the compound’s reactivity and binding affinity, making it a promising candidate for further derivatization. Such structural features are often exploited in the development of kinase inhibitors, antiviral agents, and other therapeutic compounds.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol with target proteins with high accuracy. Studies suggest that this compound exhibits favorable interactions with enzymes involved in metabolic pathways, positioning it as a potential lead for drug discovery efforts. For instance, its ability to modulate the activity of Janus kinases (JAKs) has been explored in preclinical studies aimed at developing treatments for inflammatory disorders.

The synthesis of 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol involves multi-step organic transformations, including condensation reactions, nucleophilic substitutions, and functional group modifications. The use of modern catalytic systems has improved the efficiency and selectivity of these processes, allowing for scalable production. Researchers have also investigated green chemistry approaches to minimize waste and enhance sustainability in its synthesis.

In the realm of medicinal chemistry, derivatives of 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol have shown promise in addressing unmet medical needs. For example, modifications at the 5-position have led to compounds with enhanced solubility and bioavailability, critical factors for clinical efficacy. Additionally, structural analogs have been screened for their ability to inhibit specific enzymes or receptors implicated in diseases such as cancer and neurodegeneration.

The pharmacokinetic properties of 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol are another area of active investigation. By optimizing its molecular structure, researchers aim to achieve desirable pharmacokinetic profiles, including prolonged half-life and reduced toxicity. Advanced techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) are employed to characterize the compound’s metabolic fate and excretion pathways.

Collaborative efforts between academic institutions and pharmaceutical companies have accelerated the development pipeline for 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol derivatives. Preclinical studies have demonstrated their potential in animal models, paving the way for human clinical trials. These trials are designed to evaluate safety profiles and therapeutic efficacy across various disease indications.

The future directions for research on 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol include exploring its role in combination therapies. By pairing this compound with other bioactive agents, researchers hope to achieve synergistic effects that could improve treatment outcomes. Furthermore, innovations in drug delivery systems may enhance the targeted delivery of 2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol derivatives to specific tissues or cells.

In conclusion,2-(dimethylamino)-4,6-dimethylpyrimidin-5-ol (CAS No. 345642-90-2) represents a compelling area of study in pharmaceutical chemistry. Its unique structural features and potential biological activities position it as a key intermediate in drug discovery efforts aimed at addressing diverse therapeutic challenges. As research progresses，this compound is likely to play an increasingly important role in the development of next-generation therapeutics.

• 107361-61-5(2-(dimethylamino)-4-phenylpyrimidin-5-ol)
• 685897-68-1(2-amino-4,6-dimethylpyrimidin-5-ol)
• 92635-40-0(2-(dimethylamino)-4-methylpyrimidin-5-ol)
• 1749-71-9(5-Methoxy-4-methylpyrimidin-2-amine)
• 92635-35-3(5-Pyrimidinol, 2-(ethylamino)-4-methyl-)
• 92635-36-4(2-(Hexylamino)-4-methylpyrimidin-5-OL)
• 92635-39-7(5-Pyrimidinol, 4-methyl-2-[(phenylmethyl)amino]-)
• 112934-56-2(5-Pyrimidinol, 2-(dimethylamino)-4-(3-methylphenyl)-)
• 637363-33-8(5-PYRIMIDINOL, 2-(DIMETHYLAMINO)-4,6-BIS(1,1-DIMETHYLETHYL)-)
• 92635-38-6(5-Pyrimidinol, 2-amino-4-methyl- (9CI))